AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16416102
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy agents (PTA) applied five times a week for 3 weeks
Trial: 16416102
Drug: Hylan G-F
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan G-F 20 or sodium hyaluronate (NaHA) administered weekly intra-articular during the first 3 weeks and in the sixth month
Trial: 14735021
Drug: Subarachnoid anaesthesia
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid anaesthesia with 12.75 mg 0.5% hyperbaric bupivacaine
Trial: 14735021
Drug: Subarachnoid anaesthesia
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid anaesthesia with 12.75 mg 0.5% hyperbaric bupivacaine and 15 mg fentanyl
Trial: 8615356
Drug: Synthetic beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic beta-carotene (40 mg daily for 14 days)
Trial: 8615356
Drug: Natural beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural beta-carotene from Dunaliella bardawil (40 mg daily for 14 days)
Trial: 6706069
Drug: 3-day clear
RxNorm normalized name: clear days ahead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day clear liquid diet with laxatives and enemas
Trial: 6706069
Drug: 3-day minimum-residue
RxNorm normalized name: Human t-PA (residues 1-3 and 176-527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day minimum-residue diet with laxatives and enemas
Trial: 6706069
Drug: 1-day minimum-residue
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted 1 UNT [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day minimum-residue diet with laxatives and enemas
Trial: 31241491
Drug: Topical nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical nifedipine 3% ointment
Trial: 29297588
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for lichen planopilaris
Trial: 25318000
Drug: Propofol &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol & sufentanil (PS) group received 0.1 μg/kg sufentanil and 1-2 mg/kg propofol
Trial: 25318000
Drug: Propofol &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol & fentanyl (PF) group received 1 μg/kg fentanyl and 1-2 mg/kg propofol
Trial: 25318000
Drug: Propofol &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol & remifentanil (PR) group received 1 μg/kg remifentanil and 1-2 mg/kg propofol
Trial: 25318000
Drug: Propofol &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol & half-fentanil (Pf) group received 0.5 μg/kg fentanyl and 1-2 mg/kg propofol
Trial: 25318000
Drug: Propofol &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol & half-sufentanil (Ps) group received 0.05 μg/kg sufentanil and 1-2 mg/kg propofol
Trial: 25318000
Drug: Propofol &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol & half-remifentanil (Pr) group received 0.5 μg/kg remifentanil and 1-2 mg/kg propofol
Trial: 22318246
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose CsA
Trial: 11819152
Drug: Anticholinergic drug
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic drug withdrawal
Trial: 2481671
Drug: Single-agent regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent regimens
Trial: 31474719
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of midazolam at doses of 5, 15, and 30 µg/kg
Trial: 31474719
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of midazolam at doses of 15, 50, and 100 µg/kg
Trial: 31474719
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of midazolam after oral administration
Trial: 28736211
Drug: Modern neuroscience
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern neuroscience approach (pain neuroscience education and cognition-targeted exercise therapy)
Trial: 21127424
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen 800 mg every 6 hours for 120 hours (5 days)
Trial: 19455620
Drug: Ambrisentan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan (10 mg) with Tadalafil (40 mg QD)
Trial: 19455620
Drug: Tadalafil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (40 mg) with Ambrisentan (10 mg QD)
Trial: 19455620
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ambrisentan and Tadalafil
Trial: 16335787
Drug: Garlic pearls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic pearls (GP) 250 mg per day for 2 months
Trial: 11198728
Drug: Nisoldipine (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10-40 mg)
Trial: 11198728
Drug: Amlodipine (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5-10 mg)
Trial: 8285333
Drug: Epidural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural diamorphine 2.5 mg
Trial: 8285333
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia using diamorphine
Trial: 3505874
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (completed personality inventory twice under standard directions)
Trial: 28139161
Drug: Liposome-encapsulated Aloe
RxNorm normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome-encapsulated Aloe vera gel extract (AGE) for 5 weeks
Trial: 23545908
Drug: Skin-lightening cream
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Skin-lightening cream (SLC) with 4% hydroquinone (HQ)
Trial: 23545908
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream (TCC) with 4% hydroquinone (HQ), 0.05% tretinoin, and 0.01% fluocinolone acetonide
Trial: 23545908
Drug: Skin-lightening cream
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Skin-lightening cream (SLC)
Trial: 23545908
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream (TCC)
Trial: 23545908
Drug: Both creams
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both creams
Trial: 16991077
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of trivalent inactivated influenza vaccine (TIV)
Trial: 16991077
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of trivalent inactivated influenza vaccine (TIV)
Trial: 11444449
Drug: IT morphine
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT morphine 300 microg
Trial: 7996111
Drug: Salicylic acid
RxNorm normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylic acid (2 x 250 mg)
Trial: 7996111
Drug: Acetaminophen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (2 x 250 mg)
Trial: 7996111
Drug: Ibuprofen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (2 x 250 mg)
Trial: 7996111
Drug: Ketoprofen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (2 x 250 mg)
Trial: 7996111
Drug: Acetaminophen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (2 x 250 mg) plus codeine (2 x 250 mg)
Trial: 7996111
Drug: Penicillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (2 x 250 mg)
Trial: 7996111
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base (2 x 250 mg)
Trial: 7996111
Drug: Penicillin plus
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin plus ibuprofen (2 x 250 mg)
Trial: 7996111
Drug: Methylprednisolone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (2 x 250 mg) plus penicillin (2 x 250 mg)
Trial: 31957958
Drug: Anhydrous gel
RxNorm normalized name: SiloMac Anhydrous Gel
DrugBank: Sodium sulfate (DB09472)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anhydrous gel with TriHex peptides
Trial: 29746713
Drug: SCY-078 (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCY-078 (1250 mg loading dose on day 1 followed by 750 mg once daily for 7 days)
Trial: 29746713
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg single oral dose)
Trial: 24568171
Drug: In-office light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office light plus 25 percent hydrogen-peroxide whitening gel treatment (In-office group)
Trial: 18272931
Drug: 1 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/d GPLC
Trial: 18272931
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d GPLC
Trial: 18772447
Drug: Low-dose rt-PA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rt-PA (0.3 mg/kg or 0.45 mg/kg) plus eptifibatide (75 microg/kg bolus followed by 0.75 microg/kg per min infusion for 2 hours)
Trial: 18772447
Drug: Standard-dose rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose rt-PA (0.9 mg/kg)
Trial: 18772447
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment group (low-dose rt-PA plus eptifibatide)
Trial: 18772447
Drug: Standard-dose rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose rt-PA group
Trial: 30293364
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment group
Trial: 15889948
Drug: Olanzapine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-20 mg/day, N = 370)
Trial: 15889948
Drug: Olanzapine/fluoxetine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/fluoxetine combination (6/25, 6/50, or 12/50 mg/day; N = 86)
Trial: 12534412
Drug: Nitazoxanide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (100 mg b.d. for age 2-3 years; 200 mg b.d. for age 4-11 years; 500 mg b.d. for age > 12 years)
Trial: 10818026
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose control policy with a sulphonylurea or insulin
Trial: 8679354
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lignocaine-prilocaine) applied for 8 hours after burn injury
Trial: 8679354
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment applied to contralateral leg
Trial: 8679354
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lignocaine-prilocaine)
Trial: 7049583
Drug: Chlormezanone 200
RxNorm normalized name: chlormezanone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormezanone 200 mg
Trial: 30445896
Drug: Cabotegravir LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabotegravir LA 800 mg every 12 weeks after 4 weeks of oral cabotegravir 30 mg
Trial: 30445896
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) every 12 weeks after 4 weeks of placebo tablets
Trial: 19641353
Drug: Standard RRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard RRP without suspension operation (group 2)
Trial: 17656420
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin D 800 iu plus calcium 1,200 mg
Trial: 17656420
Drug: Daily calcium
RxNorm normalized name: Calcium Carbonate/Vitamin D 600 MG-125 IU Oral Tablet [DAILY CALCIUM + VITAMIN D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily calcium 1,200 mg (Control)
Trial: 16306204
Drug: AA1.5 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA1.5 (1.5 g/kg/d for 20 h followed by 3.0 g/kg/d for 5 h)
Trial: 16306204
Drug: AA3.0 (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA3.0 (3.0 g/kg/d for 20 h followed by 1.5 g/kg/d for 5 h)
Trial: 16306204
Drug: AA-Ext (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA-Ext (1.5 g/kg/d for 20 h followed by 3.0 g/kg/d for 20 h)
Trial: 10832809
Drug: Verapamil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (5 mg i.v. + 2 microg/kg/min over 24 hours)
Trial: 3318754
Drug: Individual supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual supportive therapy
Trial: 14872504
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg three times daily
Trial: 3901756
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 or 500 mg three times daily
Trial: 30504928
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.5 mg/kg, iv
Trial: 27102820
Drug: Tetravalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent dengue vaccine (CYD-TDV)
Trial: 24112594
Drug: Chewing gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gum for at least 20 minutes every 2 hours starting at the time of capsule ingestion
Trial: 22144722
Drug: Thermal mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal mineral water at 38°C for three weeks, five times a week for 20 minutes a day plus magnetotherapy three times weekly.
Trial: 22144722
Drug: Thermal mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal mineral water at 36°C for three weeks, five times a week for 20 minutes a day plus magnetotherapy three times weekly.
Trial: 20816153
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of satisfaction between treatment groups
Trial: 18446090
Drug: High daily
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High daily dose of soy isoflavones (900 mg/day)
Trial: 16181368
Drug: TACE with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE with doxorubicin (20-60 mg) and lipiodol (2-20 mL)
Trial: 14600448
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL nonionic contrast material (300 mgI/mL) pushed with 40 mL saline solution
Trial: 14600448
Drug: 120 mL
RxNorm normalized name: 120 ML Infugem 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mL nonionic contrast material (300 mgI/mL) alone
Trial: 10386508
Drug: Warfarin sodium,
RxNorm normalized name: Warfarin Sodium, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin sodium, 1.25 mg/d
Trial: 10386508
Drug: Warfarin sodium,
RxNorm normalized name: Warfarin Sodium, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin sodium, 1.25 mg/d plus aspirin, 300 mg/d
Trial: 10386508
Drug: Aspirin, 300
RxNorm normalized name: Aspirin, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 300 mg/d
Trial: 10386508
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin therapy aiming at INR of 2.0 to 3.0
Trial: 8698374
Drug: Single 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1 g oral azithromycin
Trial: 8698374
Drug: Doxycycline, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline, 100 mg twice daily for seven days
Trial: 1898642
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion (5 micrograms/kg/min i.v.)
Trial: 25335326
Drug: Qizhi Jiangtang
RxNorm normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qizhi Jiangtang Capsule (QJC), 5 pills per time, 3 times a day
Trial: 25335326
Drug: Valsartan Capsule
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan Capsule 160 mg, once daily
Trial: 25335326
Drug: Qizhi Jiangtang
RxNorm normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qizhi Jiangtang Capsule (QJC)
Trial: 18596517
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with fenestration tubes
Trial: 15752839
Drug: ALVAC-HIV (vCP1521)/AIDSVAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV (vCP1521)/AIDSVAX B/E gp120 prime-boost vaccine
Trial: 8556996
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg kg‐1 rocuronium in obese patients
Trial: 8556996
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg kg‐1 rocuronium in all groups
Trial: 1991925
Drug: Serum PPL-specific
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PPL-specific IgE antibodies
Trial: 1991925
Drug: Serum PPL-specific
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PPL-specific IgG antibodies
Trial: 6173900
Drug: Exogenous leukocyte
RxNorm normalized name: interferon alfa-3n,human leukocyte derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous leukocyte interferon therapy as adjuvant treatment
Trial: 26977626
Drug: Mexidol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol (1000 mg/day for 14-15 days)
Trial: 24813928
Drug: Intervention of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention of antibiotic prescription recommendations evaluated on the third day by an infectious disease specialist.
Trial: 24813928
Drug: Intervention of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention of antibiotic prescription recommendations with dose adjustment or change of route.
Trial: 24813928
Drug: Intervention of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention of antibiotic prescription recommendations that were personally commented on.
Trial: 24813928
Drug: Intervention of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention of antibiotic prescription recommendations overall.
Trial: 21988468
Drug: Ceftazidime continuous
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime continuous infusion (4g after 2g loading dose for MDRD 10-30 ml/min, 6g for MDRD 40-80 ml/min, 8g for MDRD 90-110 ml/min, 10g for MDRD 120-190 ml/min, 12g/day for MDRD >200 ml/min)
Trial: 21988468
Drug: Ceftazidime continuous
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime continuous infusion
Trial: 1457267
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg as capsules) and soluble paracetamol (1 g)
Trial: 1457267
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg as capsules)
Trial: 6379120
Drug: Full dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dosage daunorubicin, cytosine arabinoside, and 6-thioguanine (F DAT)
Trial: 6379120
Drug: Attenuated dosage
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated dosage daunorubicin, cytosine arabinoside, and 6-thioguanine (At DAT)
Trial: 20089522
Drug: Dienogest (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest (2 mg/day, orally)
Trial: 18653184
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin acetate (900 microg/day, intranasally)